 |
|
Predicting Benefit for Implantable Cardioverter-Defibrillator Use
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
To the Editor: In her Editorial about disparities in the use of implantable cardioverter-defibrillators (ICDs), Dr Redberg1 raised an important question about which Medicare beneficiaries will benefit from ICDs, an issue that concerns patients, policy makers, and ICD manufacturers. The question could be expanded to all individuals at risk of sudden cardiac death who might benefit from ICD implantation, not only Medicare patients. Therefore, the issue should be whether persons who are more likely to develop sudden cardiac death and benefit from ICD therapy as primary prevention can be identified or predicted.
Developing prediction models that better identify individuals at risk of sudden cardiac death is challenging for a number of reasons. It requires distinguishing individuals at higher risk for sudden cardiac death within a lower-risk general population. The subset of persons with sudden cardiac death (who could potentially benefit from ICD use) shares the same set of traditional risk . . . [Full Text of this Article]
Elsayed Z. Soliman, MD, MSc
esoliman@wfubmc.edu
Division of Public Health
Department of Epidemiology and Prevention
Wake Forest University School of Medicine
Winston Salem, North Carolina
RELATED LETTER
Predicting Benefit for Implantable Cardioverter-Defibrillator Use—Reply
Rita F. Redberg
JAMA. 2008;299(3):287.
EXTRACT
| FULL TEXT
RELATED ARTICLE
Disparities in Use of Implantable Cardioverter-Defibrillators: Moving Beyond Process Measures to Outcomes Data
Rita F. Redberg
JAMA. 2007;298(13):1564-1566.
EXTRACT
| FULL TEXT
|
